A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells

Withdrawn

• Conditions: Non Small Cell Lung Cancer
• Interventions: Biological: Sample

• Registration Number: NCT05648188
• Lead Sponsor: Centre Hospitalier Universitaire de Nice

Brief Summary

Early non-small cell lung cancer (NSCLC), treated by surgery or radiotherapy in the case of inoperability, relapses in almost 50% of cases. Circulating tumour cells (CTCs), which can be detected before surgery, represent a promising prognostic tool, but the markers characterising their aggressiveness remain to be determined. The NSCLC microenvironment, in which purinergic signalling is a key pathway, controls tumour development. Adenosine derived from the action of CD39 and CD73 ectonucleotidases hydrolysing extracellular ATP, induces immunosuppression of NSCLC by activating A2R receptors. The expression and prognostic relevance of A2R, CD39 and CD73 on CTCs is unknown. The objectives are to (i) compare the expression of A2R and CD39 and CD73 on primary tumour cells and CTCs of patients operated on for early NSCLC, (ii) correlate these data with molecular characteristics and clinical response, (iii) determine on lung cancer lines whether irradiation impacts on the expression of A2R, CD39 and CD73. This work could contribute to the identification of new theranostic biomarkers.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-12-05
• Study First Submitted QC: 2022-12-05
• Study First Posted: 2022-12-13
• Study Start: 2023-01-01
• Primary Completion: 2024-10-30
• Study Completion: 2024-10-30
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-09
• Last Update Posted: 2025-04-10

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
NSCLC patients	Sample	Patients with proven stage IA-IIB non-small cell lung cancer (NSCLC).

Primary Outcome Measures

Name	Time	Method
Ex vivo expression of A2R (adenosine receptor), CD39, CD73 and P2RX7 on NSCLC and CTC	At inclusion	Presence versus Absence of expression (immunohistochemistry)

Secondary Outcome Measures

Name	Time	Method
In vitro impact of radiation therapy on the A2R, CD39, CD73 expression by cells lineage	At inclusion	Upregulation / Downregulation of expression (mRNA by real time PCR)

Trial Locations

Locations (1)

CHU de Nice; 🇫🇷 Nice, France